Back to Search
Start Over
Impact of second-generation antipsychotics monotherapy or combined therapy in cytokine, lymphocyte subtype, and thyroid antibodies for schizophrenia: a retrospective study.
- Source :
-
BMC psychiatry [BMC Psychiatry] 2024 Oct 16; Vol. 24 (1), pp. 695. Date of Electronic Publication: 2024 Oct 16. - Publication Year :
- 2024
-
Abstract
- Background: Schizophrenia (SCZ) shares high clinical relevance with the immune system, and the potential interactions of psychopharmacological drugs with the immune system are still an overlooked area. Here, we aimed to identify whether the second-generation antipsychotics (SGA) monotherapy or combined therapy of SGA with other psychiatric medications influence the routine blood immunity biomarkers of patients with SCZ.<br />Methods: Medical records of inpatients with SCZ from January 2019 to June 2023 were retrospectively screened from June 2023 to August 2023. The demographic data and peripheral levels of cytokines (IL-2, IL-4, IL-6, TNF-α, INF-γ, and IL-17 A), lymphocyte subtype proportions (CD3+, CD4+, CD8 + T-cell, and natural killer (NK) cells), and thyroid autoimmune antibodies (thyroid peroxidase antibody (TPOAb), and antithyroglobulin antibody (TGAb)) were collected and analyzed.<br />Results: 30 drug-naïve patients, 64 SGA monotherapy (20 for first-episode SCZ, 44 for recurrent SCZ) for at least one week, 39 combined therapies for recurrent SCZ (18 with antidepressant, 10 with benzodiazepine, and 11 with mood stabilizer) for at least two weeks, and 23 used to receive SGA monotherapy (had withdrawn for at least two weeks) were included despite specific medication. No difference in cytokines was found between the SGA monotherapy sub-groups (p > 0.05). Of note, SGA monotherapy appeared to induce a down-regulation of IFN-γ in both first (mean [95% confidence interval]: 1.08 [0.14-2.01] vs. 4.60 [2.11-7.08], p = 0.020) and recurrent (1.88 [0.71-3.05] vs. 4.60 [2.11-7.08], p = 0.027) episodes compared to drug-naïve patients. However, the lymphocyte proportions and thyroid autoimmune antibodies remained unchanged after at least two weeks of SGA monotherapy (p > 0.05). In combined therapy groups, results mainly resembled the SGA monotherapy for recurrent SCZ (p > 0.05).<br />Conclusion: The study demonstrated that SGA monotherapy possibly achieved its comfort role via modulating IFN-γ, and SGA combined therapy showed an overall resemblance to monotherapy.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Male
Female
Retrospective Studies
Adult
Middle Aged
Lymphocyte Subsets immunology
Lymphocyte Subsets drug effects
Iodide Peroxidase immunology
Schizophrenia drug therapy
Schizophrenia immunology
Schizophrenia blood
Antipsychotic Agents therapeutic use
Cytokines blood
Cytokines immunology
Autoantibodies blood
Autoantibodies immunology
Drug Therapy, Combination
Subjects
Details
- Language :
- English
- ISSN :
- 1471-244X
- Volume :
- 24
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- BMC psychiatry
- Publication Type :
- Academic Journal
- Accession number :
- 39415112
- Full Text :
- https://doi.org/10.1186/s12888-024-06141-z